A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
Open Access
- 1 November 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (10) , 1329-1336
- https://doi.org/10.1038/bjc.1998.679
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.1995
- Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy.1994
- Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating FactorJNCI Journal of the National Cancer Institute, 1993
- Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.1993
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.1992
- A model for tumor cell killing by topoisomerase poisons.1990
- DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in XenograftsScience, 1989
- Reporting results of cancer treatmentCancer, 1981
- Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).1970